Myeloid‑derived suppressor cells infiltration in non‑small‑cell lung cancer tumor and MAGE‑A4 and NY‑ESO‑1 expression
- Authors:
- Zhenbo Hou
- Xiao Liang
- Xinmei Wang
- Ziqiang Zhou
- Guilan Shi
-
Affiliations: Department of Pathology, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China, Department of Thoracic Surgery, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China, Department of Immunology, School of Nursing, Zibo Vocational Institute, Zibo, Shandong 255314, P.R. China - Published online on: March 31, 2020 https://doi.org/10.3892/ol.2020.11497
- Pages: 3982-3992
-
Copyright: © Hou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Carbone DP, Gandara DR, Antonia SJ, Zielinski C and Paz-Ares L: Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy. J Thorac Oncol. 10:974–984. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zeltsman M, Dozier J, McGee E, Ngai D and Adusumilli PS: CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. Transl Res. 187:1–10. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mayor M, Yang N, Sterman D, Jones DR and Adusumilli PS: Immunotherapy for non-small cell lung cancer: Current concepts and clinical trials. Eur J Cardiothorac Surg. 49:1324–1333. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shroff GS, de Groot PM, Papadimitrakopoulou VA, Truong MT and Carter BW: Targeted therapy and immunotherapy in the treatment of non-small cell lung cancer. Radiol Clin North Am. 56:485–495. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M and Spagnoli GC: Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer. 120:337–343. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria S and Jungbluth AA: Expression of cancer testis antigens in human BRCA-associated breast cancers: Potential targets for immunoprevention? Cancer Immunol Immunother. 60:999–1007. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A and Old LJ: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 187:1349–1354. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Mahmoud AM: Cancer testis antigens as immunogenic and oncogenic targets in breast cancer. Immunotherapy. 10:769–778. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gjerstorff MF, Andersen MH and Ditzel HJ: Oncogenic cancer/testis antigens: Prime candidates for immunotherapy. Oncotarget. 6:15772–15787. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Silina K, Zayakin P, Kalnina Z, Ivanova L, Meistere I, Endzeliņš E, Abols A, Stengrēvics A, Leja M, Ducena K, et al: Sperm-associated antigens as targets for cancer immunotherapy: Expression pattern and humoral immune response in cancer patients. J Immunother. 34:28–44. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cogdill AP, Frederick DT, Cooper ZA, Garber HR, Ferrone CR, Fiedler A, Rosenberg L, Thayer SP, Warshaw AL and Wargo JA: Targeting the MAGE A3 antigen in pancreatic cancer. Surgery. 152 (3 Suppl 1):S13–S18. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, et al: Chemokine-driven lymphocyte infiltration: An early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 61:427–438. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Benchetrit F, Gazagne A, Adotevi O, Haicheur N, Godard B, Badoual C, Fridman WH and Tartour E: Cytotoxic T lymphocytes: Role in immunosurveillance and in immunotherapy. Bull Cancer. 90:677–685. 2003.(In French). PubMed/NCBI | |
|
Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D and Freedman RS: Immune responses to human tumors: Development of tumor vaccines. Anticancer Res. 23:1969–1996. 2003.PubMed/NCBI | |
|
Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC and Resnick MB: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res. 9:6453–6460. 2003.PubMed/NCBI | |
|
Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H and Nishimura T: Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol. 28:1089–1098. 2006.PubMed/NCBI | |
|
Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, et al: Circulating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancer. Am J Respir Crit Care Med. 198:777–787. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ortiz ML, Lu L, Ramachandran I and Gabrilovich DI: Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res. 2:50–58. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Zhang Y and Zhang L: Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy. J Cancer Res Clin Oncol. 145:281–291. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Baran CA, Agaimy A, Wehrhan F, Weber M, Hille V, Brunner K, Wickenhauser C, Siebolts U, Nkenke E, Kesting M and Ries J: MAGE-A expression in oral and laryngeal leukoplakia predicts malignant transformation. Mod Pathol. 32:1068–1081. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jin S, Cao S, Li J, Meng Q, Wang C, Yao L, Lang Y, Cao J, Shen J, Pan B, et al: Cancer/testis antigens (CTAs) expression in resected lung cancer. Onco Targets Ther. 11:4491–4499. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kakimoto T, Matsumine A, Kageyama S, Asanuma K, Matsubara T, Nakamura T, Iino T, Ikeda H, Shiku H and Sudo A: Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma. Oncol Lett. 17:3937–3943. 2019.PubMed/NCBI | |
|
Ueda S, Miyahara Y, Nagata Y, Sato E, Shiraishi T, Harada N, Ikeda H, Shiku H and Kageyama S: NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma. Oncotarget. 9:35997–36011. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmermann AK, Imig J, Klar A, Renner C, Korol D, Fink D, Stadlmann S, Singer G, Knuth A, Moch H and Caduff R: Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. Virchows Arch. 462:565–574. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D, Georgoulias V and Kotsakis A: A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res. 2014:6592942014. View Article : Google Scholar : PubMed/NCBI | |
|
Lang S, Bruderek K, Kaspar C, Höing B, Kanaan O, Dominas N, Hussain T, Droege F, Eyth C, Hadaschik B and Brandau S: Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets. Clin Cancer Res. 24:4834–4844. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grauers Wiktorin H, Nilsson MS, Kiffin R, Sander FE, Lenox B, Rydström A, Hellstrand K and Martner A: Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Cancer Immunol Immunother. 68:163–174. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Barrera L, Montes-Servin E, Hernandez-Martinez JM, Orozco-Morales M, Montes-Servín E, Michel-Tello D, Morales-Flores RA, Flores-Estrada D and Arrieta O: Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer. Cancer Immunol Immunother. 67:1393–1406. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rusch VW, Crowley J, Giroux DJ, Goldstraw P, Im JG, Tsuboi M, Tsuchiya R and Vansteenkiste J; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions, . The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2:603–612. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Schacht V and Kern JS: Basics of immunohistochemistry. J Invest Dermatol. 135:1–4. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Grah J, Samija M, Juretić A, Sarcević B and Sobat H: Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: The relationship with clinical-pathological features. Coll Antropol. 32:731–736. 2008.PubMed/NCBI | |
|
Hamilton G and Rath B: Immunotherapy for small cell lung cancer: Mechanisms of resistance. Expert Opin Biol Ther. 19:423–432. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wei X, Chen F, Xin K, Wang Q, Yu L, Liu B and Liu Q: Cancer-Testis antigen peptide vaccine for cancer immunotherapy: Progress and prospects. Transl Oncol. 12:733–738. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Grah JJ, Katalinic D, Juretic A, Santek F and Samarzija M: Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori. 100:60–68. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Smith SM and Iwenofu OH: NY-ESO-1: A promising cancer testis antigen for sarcoma immunotherapy and diagnosis. Chin Clin Oncol. 7:442018. View Article : Google Scholar : PubMed/NCBI | |
|
Su C, Xu Y, Li X, Ren S, Zhao C, Hou L, Ye Z and Zhou C: Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer. Int J Clin Exp Pathol. 8:5509–5518. 2015.PubMed/NCBI | |
|
John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, et al: The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One. 8:e678762013. View Article : Google Scholar : PubMed/NCBI | |
|
Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda M, Kinoshita A, et al: Serum antibody against NY-ESO-1 and XAGE1 antigens potentially predicts clinical responses to anti-PD-1 therapy in non-small-cell lung cancer. J Thorac Oncol. 14:2071–2083. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Giavina-Bianchi M, Giavina-Bianchi P, Sotto MN, Muzikansky A, Kalil J, Festa-Neto C and Duncan LM: Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma. J Immunol Res. 2015:7613782015. View Article : Google Scholar : PubMed/NCBI | |
|
Nazemalhosseini-Mojarad E, Mohammadpour S, Torshizi Esafahani A, Gharib E, Larki P, Moradi A, Amin Porhoseingholi M, Asadzade Aghdaei H, Kuppen PJK and Zali MR: Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features. J Cell Physiol. 234:4768–4777. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F and Woller N: CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 75:689–713. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, et al: Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell. 176:775–789.e718. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, Nizze H and Barten M: Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 35:808–816. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Knocke S, Fleischmann-Mundt B, Saborowski M, Manns MP, Kühnel F, Wirth TC and Woller N: Tailored tumor immunogenicity reveals regulation of CD4 and CD8 T cell responses against cancer. Cell Rep. 17:2234–2246. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F and Vermorken JB: Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 11:192010. View Article : Google Scholar : PubMed/NCBI | |
|
Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, et al: Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 109:1103–1112. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Feng PH, Lee KY, Chang YL, Chan YF, Kuo LW, Lin TY, Chung FT, Kuo CS, Yu CT, Lin SM, et al: CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Criti Care Med. 186:1025–1036. 2012. View Article : Google Scholar | |
|
Li YD, Lamano JB, Lamano JB, Quaggin-Smith J, Veliceasa D, Kaur G, Biyashev D, Unruh D and Bloch O: Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer. Cancer Immunol Immunother. 68:1501–1513. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 166:678–689. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P and Van Ginderachter JA: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 111:4233–4244. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaraj S and Gabrilovich DI: Myeloid-derived suppressor cells. Adv Exp Med Biol. 601:213–223. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, Choi KU, Kim JY, Park DY and Sol MY: Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung. 187:401–411. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Haier J, Owzcareck M, Guller U, Spagnoli GC, Bürger H, Senninger N and Kocher T: Expression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomas. Anticancer Res. 26:2281–2287. 2006.PubMed/NCBI | |
|
Al-Khadairi G and Decock J: Cancer testis antigens and immunotherapy: Where do we stand in the targeting of PRAME? Cancers (Basel). 11:E9842019. View Article : Google Scholar : PubMed/NCBI | |
|
Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M and Maio M: Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res. 64:9167–9171. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Z, Hosseini Bereshneh A and Rezaei N: Cancer/Testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 45:619–640. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Nicolay HJ, Sigalotti L and Maio M: The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol Oncol. 5:164–182. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E and Lübbert M: The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 34:899–905. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Song X, Song W, Wang Y, Wang J, Li Y, Qian X, Pang X, Zhang Y and Yin Y: MicroRNA-874 functions as a tumor suppressor by targeting cancer/testis antigen HCA587/MAGE-C2. J Cancer. 7:656–663. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D and Decock J: NY-ESO-1 based immunotherapy of cancer: Current perspectives. Front Immunol. 9:9472018. View Article : Google Scholar : PubMed/NCBI | |
|
Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, et al: A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol. 186:685–696. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Peng JR, Chen HS, Mou DC, Cao J, Cong X, Qin LL, Wei L, Leng XS, Wang Y and Chen WF: Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett. 219:223–232. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A and Keilholz U: Natural T cell immunity against cancer. Clin Cancer Res. 9:4296–4303. 2003.PubMed/NCBI | |
|
Chen YT, Chiu R, Lee P, Beneck D, Jin B and Old LJ: Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. Hum Reprod. 26:3232–3243. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rivera MP and Stover DE: Gender and lung cancer. Clin Chest Med. 25:391–400. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Barrera-Rodriguez R and Morales-Fuentes J: Lung cancer in women. Lung Cancer (Auckl). 3:79–89. 2012.PubMed/NCBI | |
|
Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, Ko JS, Lu MC and Feng AC: Sex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor? Lung Cancer. 66:262–267. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sakurai H, Asamura H, Goya T, Eguchi K, Nakanishi Y, Sawabata N, Okumura M, Miyaoka E and Fujii Y; Japanese Joint Committee for Lung Cancer Registration, : Survival differences by gender for resected non-small cell lung cancer: A retrospective analysis of 12,509 cases in a Japanese lung cancer registry study. J Thorac Oncol. 5:1594–1601. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shi G, Wang H and Zhuang X: Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model. Oncol Lett. 11:809–816. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Perkins NJ and Schisterman EF: The inconsistency of ‘optimal’ cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 163:670–675. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hajian-Tilaki K: Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med. 4:627–635. 2013.PubMed/NCBI | |
|
Obuchowski NA and Bullen JA: Receiver operating characteristic (ROC) curves: Review of methods with applications in diagnostic medicine. Phys Med Biol. 63:07TR012018. View Article : Google Scholar : PubMed/NCBI | |
|
Carter JV, Pan J, Rai SN and Galandiuk S: ROC-ing along: Evaluation and interpretation of receiver operating characteristic curves. Surgery. 159:1638–1645. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kamarudin AN, Cox T and Kolamunnage-Dona R: Time-dependent ROC curve analysis in medical research: Current methods and applications. BMC Med Res Methodol. 17:532017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang G, Huang H, Zhu Y, Yu G, Gao X, Xu Y, Liu C, Hou J and Zhang X: A novel subset of B7-H3(+)CD14(+)HLA-DR(−/low) myeloid-derived suppressor cells are associated with progression of human NSCLC. Oncoimmunology. 4:e9771642015. View Article : Google Scholar : PubMed/NCBI | |
|
Marvel D and Gabrilovich DI: Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest. 125:3356–3364. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kaplan RM, Chambers DA and Glasgow RE: Big data and large sample size: A cautionary note on the potential for bias. Clin Transl Sci. 7:342–346. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson SF, Kelley K and Maxwell SE: Sample-size planning for more accurate statistical power: A method adjusting sample effect sizes for publication bias and uncertainty. Psychol Sci. 28:1547–1562. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Biau DJ, Kerneis S and Porcher R: Statistics in brief: The importance of sample size in the planning and interpretation of medical research. Clin Orthop Relat Res. 466:2282–2288. 2008. View Article : Google Scholar : PubMed/NCBI |
